This study established a method to create stem cell-derived dermal papilla cells and found that their conditioned medium significantly boosts hair growth and offers anti-inflammatory benefits in mice, surpassing minoxidil and addressing androgen-related hair loss.
This study found that cell-free fat extract (CEFFE) enhanced hair growth in mice with androgenetic alopecia by increasing hair follicle density and promoting proliferation while regulating the DHT/AR pathway.
2 citations
,
September 2018 in “Tissue Engineering Part A”
This study found that injecting xeno-free, three-dimensional cell masses from human adipose-derived stem cells improved blood perfusion and preserved limb function in mice without causing tumors or toxicity, suggesting potential for treating severe ischemic diseases.
A user plans a drug-free hair transplant while waiting for future treatments like stem celltherapies, which are projected to be available between 2028 and 2030. Many users express skepticism about the availability of new treatments, suggesting that relying on them is risky and that finasteride remains the most effective option.
A user's father experienced hair regrowth and other health improvements after two IV exosome treatments. The user also had four rounds of exosome therapy, noting significant hair regrowth and relief from headaches, but no change in gray hair.
Stem cell and PRP therapy for hair loss is considered experimental and not consistently effective. Treatments like finasteride, minoxidil, and hair transplants are more established, but the potential for cloning chemically resistant hair follicles is seen as a promising future solution.
Hair loss treatments like finasteride, minoxidil, and hair transplants have side effects and limitations. There is hope for future advancements in stem celltherapy and hair follicle regeneration, though skepticism about their effectiveness and timeline persists.
Pelage is developing a topical hair follicle stem celltherapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.